SUSTAINED MICRODOSE

TECHNOLOGY™

Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds: Psilocybin, MDMA, DMT, LSD, & Ketamine by the United States Drug Enforcement Agency (DEA).

contact us

Company Highlights

Mycrodose Therapeutics believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

THERAPEUTICS

  • Mission Driven Team
  • US Pharmaceutical BioTech Company
  • Core Expertise is Developing Advanced Drug Delivery Products 
  • Main Indications for our ADD Products are in Mental Health & Cognitive Diseases using Psychedelic APIs. 

TECHNOLOGY

  • The company’s core product line utilizes its IP-protected Sustained Microdose Technology™ to safely deliver a highly accurate and therapeutic dose of Psychedelic API’s (Active Pharmaceutical Ingredient)
  • Technology can be used for both micro and macro dose
  • Comprehensive Patent Filed & Growing Pipeline
  • Development of Core Technologies can be both highly expandable and largely scalable with collaborations, such as with our collaboration of Orphan Drug Indication for Fragile X Syndrome (FXS).

LABORATORY

  • 3700sf R&D Laboratory in San Diego, CA
  • Lab work and clinical supply production follow GLP and GMP regulations.  
  • Approved by the Attorney General in California, DEA, and FDA for Research of 4 Schedule I Psychedelic APIs including Psilocybin, LSD, MDMA, and DMT. Lab also approved for Ketamine & Cannabis
  • Fully built out state of the art analytical, R&D, and Product development departments.

our team

Management Team

The company’s C-Suite has over 100 years of combined experience developing patented drug delivery technologies, a successful track-record of working with the FDA and navigating the clinic trial process, and a proven history of core business fundamentals and successful M&A ventures.

CHAD CONNER

Chief Executive Officer

  • 20 year entrepreneurial veteran in cannabis wellness, holistic medicine, pharmaceutical, and integrative health treatment clinics. 
  • Founded and Sold Pure Ratios to 4Front Ventures (FFNTF).
  • Successful exit through Capital Markets.
  • Physician for over 20 years specializing in Mental Health.

PATRICK ECKSTROM

Chief Operating Officer

  • 15 years of Executive-level experience building & developing successful companies through proven operational efficiencies and data-driven decisions.
  • Expert customer acquisition and customer retention professional targeting B2B and B2C channels effectively generating $1MM+ in MRR.
  • Owned and Operated multiple digital marketing Agencies for over 10 years.

FRANK KOCHINKE, PHD.

Chief Science Officer

  • 35 years of Pharmaceutical Industry experience in Advanced Drug Delivery Systems based on Sustained and Controlled Release.
  • Specializing in Transdermal, Buccal, and Biodegradable Implant technologies.
  • Published over 50 papers and holds 16 patents.
  • Successful exits one of which sold with his former company, Oculex, for $400MM to Allergan.

INSTITUTIONAL INVESTMENT PARTNERS

Henri Sant-Cassia, Founding Partner, The Conscious Fund

"Mycrodose is leading the evolution of drug delivery in psychedelic medicine. We are delighted to be helping their impressive team to build a company with importance to the entire sector. Their expertise and track record in creating successful exits set them apart. Ultimately, we believe their work will improve patient experiences and outcomes."

Cody Shandraw, Director for Ambria Capital, LLC

"Mycrodose Therapeutics has everything we look for when making an investment; skilled business planning with accretive targets, a robust technology portfolio and a well-established management team. We are witnessing the evolution of the healthcare/psychedelic sector and we believe Mycrodose with their proprietary intellectual property is one of the companies leading the change. By working with the executive team at Mycrodose we've been able to make another meaningful investment into the future of psychedelic medicines, there's a positive outlook for the year ahead and it's been a great start to the year for the company."

Ken Belotsky, Partner, Negev Capital

''Negev capital is delighted to support Mycrodose Therapeutics as they enter a new phase of development. We have invested in Mycrodose based on their impressive team, strategic vision, and tangible assets in drug delivery technology and processes…We expect the value of Mycrodose Therapeutics to increase substantially as this excellent team guides the development of innovative delivery technologies...''

Adrain Morante, Vice President, K2 & Associates

“I’ve looked at nearly all the investment opportunities within the psychedelic sector over the last year and very few companies have the experienced team needed to navigate the FDA or the ability to create unique and patented products the way that Mycrodose Therapeutics has already proven to be able to do.” 

MARKET SIZES & PROJECTIONS

$310 BILLION

GLOBAL MARKET

Advanced Drug Delivery Systems

The global market for advanced drug delivery systems will grow from $231 billion in 2020 to $310 billion by 2025. Mycrodose Therapeutics’ core business model and experience is in successfully developing these delivery systems for Psychedelic APIs to treat mental health.

2021 ESTIMATE

MARKET SIZE (US$M)*

*Psilocybin Transdermal System

Obesity

$6,460M

Autism

$5,300M

Depression

$2,800M

THERAPEUTICS

MARKET SHARE (US$M)*

*Psilocybin Transdermal 

Obesity

$182M

Autism

$159M

Depression

$84M

IMPORTANCE OF ADVANCED DRUG DELIVERY (ADD)

WITH PSYCHEDELIC API’S

ADD - Controlled & Sustained Release

A. ADD products Control Input Rate into Blood

  • Plasma level controls brain activity (entropy, receptor occupancy)
  • Brain activity correlated w/Therapeutic Result (intensity rating)

B. ADD products Sustain the Input over prolonged periods of time

  • Allowing Physician to Titrate dosage over time to get optimal results

ADD - Benefits

  • High safety profile
  • Increased Bioavailability
  • Less active ingredient 
  • Better efficacy
  • Fewer side effects
  • Convenience
  • For Children, Adults, and Elderly
  • Faster pathway to/thru the FDA   

THE “PEAKS & VALLEYS” ISSUES SOLVED!

PEAKS

Waste drug, create adverse reactions

VALLEYS

No Therapy

Standard Drug Delivery Methods Have Issues

PEAKS

  • Wasted Drug (APIs)
  • Adverse Reaction
  • Harmful Toxicity
  • Psychosis or Permanent 
  • Mental Health Issues

VALLEYS

  • Micro Spikes
  • Limited Therapeutic Benefit
  • Gaps Between Treatments

OUR PRODUCTS GIVE THE PHYSICIAN THE TOOLS TO CONTROL

CORE ADVANCED DRUG DELIVERY TECHNOLOGIES

Core Advanced Drug Delivery Technologies

Transdermal Delivery of Psilocybin (Transdermal Patch)

Our IP Protected transdermal technology delivers a sustained and controlled dose of medicine directly into the bloodstream, bypassing the liver, to reduce the potential of harmful toxicity, psychosis, and the common issues associated with standard macro dosing products. 

Transdermal Patches

Transmucosal Delivery of Ketamine (Lozenge)

Our IP Protected transmucosal lozenge technology also delivers a sustained and controlled dose of medicine into the body slowly over time. Our technology offers an advantage to other sublingual.

Transmucosal Lozenges

COMPANY TIMELINE & CLINICAL PIPELINE

PARTNERSHIPS & COLLABORATION

Mycrodose Therapeutics is working on several lucrative agreements to co-develop & license products that will be sold in Phase 1/2 FDA studies or brought to commercialization. In addition, agreements are set in place to create revenues through distribution of API’s.

COMPETITIVE ADVANTAGE

CRITERIA MYCRODOSE THERAPEUTICS
Primary Dosing TechnologySustained & Controlled Microdose
Therapy Assisted or Unassisted Treatment w/ API Both Option (Blockbuster)
Advanced Drug Delivery TechnologiesFour (4)
Proprietary position of sustained release to control brain activity and occupancy rates Yes
Able to control delivery to desired plasma concentration correlated to therapeutic outcomesYes
Technology Safer for Children, Adults, and ElderlyYes
Product Revenues Through Multiple VehiclesPartnerships, Product Exit/Licensing
Established Company, Milestone Driven, Series A Investment RoundPrivate

1,000,000,000 PEOPLE IMPACTED BY MENTAL HEALTH

Mycrodose Therapeutics started from a deep personal need to find better solutions for treating mental health. We have a deep desire of improving the fight against the mental health pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe.

Investor Relations & Media Requests for Mycrodose Therapeutics Contact:

Company News & Media Coverage:

Where can I get some?

Nov 09, 2021 Patrick Eckstrom

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. 

Read More

Where does it come from?

Nov 09, 2021 Patrick Eckstrom

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. 

Read More

The standard Lorem Ipsum passage, used since the 1500s

Nov 09, 2021 Patrick Eckstrom

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. 

Read More